STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 21 - Issue 4, October-December 2019
SHORT REPORTS
IMMUNE CHECKPOINT INHIBITOR-INDUCED PNEUMONITIS: CASE REPORT
CARRIÓN MADROÑAL ISABEL MARÍA, MORALES PANCORBO DAVID, JIMÉNEZ RUIZ FRANCISCO JAVIER, GARCÍA SAMBLÁS VICTORIA, GARRIDO MARTÍNEZ MARÍA TERESA


Today, oncological immunotherapy is a biological therapy that constitutes a new
tool for treating solid tumors stimulating the immune system to combat cancer.
Pembrolizumab is an example of an anti-PD-1 drug that unblocks T-cell inhibition
and induces immune system activation.
Pneumonitis (interstitial lung disease) is a severe adverse event in patients
treated with anti-PD-1 drugs that has even been linked to respiratory failure and
death.
We present the case of a 70-year-old patient diagnosed with lung adenocarcinoma
undergoing treatment w th chemotherapy and pembrolizumab. After seven
cycles, the patient was hospitalized i
in the oncology unit for dyspnea, fever and
pulmonary infiltrate. The patient presented respiratory failure with no response to
corticoids or broad spectrum antibiotics. The chest CT showed probable pneumonitis
secondary to immunotherapy. In line with current guidelines, an immunosuppressant
therapy was initiated with infliximab 5 mg/kg to reverse toxic effects. Six
days after initiating treatment with infliximab, and admission in Intensive Care
Unit had been dismissed, the patient died due to respiratory failure.


ADVERSE EVENT – IMM UNE CHECKPOINT INHIBITOR – IMM UNOTHERAPY –
INFLIXIMAB – PEMBROLIZUMAB – PNEUMONITIS



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25